• Q-VD(OMe)-OPh: Precision Caspase Inhibition for Apoptosis Re

  2026-04-29

  Q-VD(OMe)-OPh, a potent pan-caspase inhibitor from APExBIO, empowers researchers to dissect apoptotic pathways with extraordinary specificity and low toxicity. Its robust performance in apoptosis assays, cancer differentiation protocols, and neuroprotection studies positions it as an essential tool for translational breakthroughs in cell death research.

• Temafloxacin: Enhancing Fluoroquinolone Antibacterial Assays

  2026-04-29

  Temafloxacin stands out as a fluoroquinolone broad-spectrum antibacterial agent with proven efficacy against both Gram-positive and Gram-negative bacteria, as well as intracellular pathogens. This guide delivers actionable workflows, troubleshooting tips, and comparative insights to optimize advanced antibacterial and intracellular bactericidal assays for research applications.

• SAR Probing of KX2-391 Analogues: New Insights into Kinase S

  2026-04-28

  Omar et al.'s study systematically explores how structural modifications of KX2-391 dihydrochloride analogues affect their inhibition profiles across major oncogenic kinases. Their findings reveal that scaffold-hopping can dramatically shift selectivity and cytotoxic mechanisms, with implications for designing novel multi-kinase inhibitors in leukemia and beyond.

• Unraveling Complete Nicotine Biosynthesis in Plants

  2026-04-28

  Chang et al. (2026) elucidate the full biosynthetic pathway of nicotine in Nicotiana species, revealing the assembly of a vacuolar five-enzyme metabolon and critical glycosylation steps. This work provides a foundation for metabolic engineering of nicotine production and advances understanding of alkaloid scaffold formation.

• Pifithrin-α (PFTα): Precision p53 Inhibition in Apoptosis Re

  2026-04-27

  Pifithrin-α is a synthetic p53 inhibitor widely used to study p53-dependent apoptosis, cell cycle arrest, and ferroptosis. This article details its mechanism, key evidence, and practical limitations. APExBIO’s A4206 formulation ensures reliable experimental performance.

• Dual-Action Inhibitors Accelerate p38α MAPK Dephosphorylatio

  2026-04-27

  This study demonstrates that certain kinase inhibitors, beyond blocking p38α MAPK activity, also promote its dephosphorylation by stabilizing an activation loop conformation accessible to phosphatases. These findings offer a mechanistic framework for designing more potent, specific kinase inhibitors and expand our understanding of kinase-phosphatase interplay.

• SB 431542 (SKU A8249): Reliable ALK5 Inhibitor for TGF-β Ass

  2026-04-26

  This scenario-driven article examines how SB 431542 (SKU A8249) addresses reproducibility, sensitivity, and workflow optimization in TGF-β signaling assays. Drawing on peer-reviewed data and real laboratory challenges, it guides researchers in choosing, applying, and interpreting results with SB 431542 for robust cell viability and immunology studies.

• Crizotinib Hydrochloride in Advanced ALK Kinase Inhibitor As

  2026-04-25

  Crizotinib hydrochloride empowers researchers to dissect ALK, c-Met, and ROS1 signaling in complex assembloid models that mimic human tumor microenvironments. This guide details optimized protocols, troubleshooting, and the translation of patient-derived cancer assembloid innovations into actionable workflows for oncogenic kinase pathway research.

• Ionomycin Calcium Salt: Advanced Dissection of Ca2+ Signalin

  2026-04-24

  Explore the multifaceted role of Ionomycin calcium salt as a calcium ionophore for advanced research into calcium signaling, apoptosis, and cancer metastasis. This article delivers a deeper mechanistic perspective and practical assay guidance, standing apart from existing content.

• Comparative Antibacterial Profiling of Cefoperazone and β-La

  2026-04-24

  This article reviews a pivotal study comparing the antibacterial activities of N-formimidoyl thienamycin (MK0787) with advanced β-lactam antibiotics, including cefoperazone, against multidrug-resistant gram-negative and gram-positive clinical isolates. The findings inform assay design, resistance studies, and strategic antibiotic selection in translational microbiology.

• Deletion of Chicken MHC Class I Gene BF1 via Direct Repeats

  2026-04-23

  This study uncovers the complete deletion of the minor class I gene BF1 in the B14 and typical B15 chicken MHC haplotypes, linked to recombination between short imperfect direct repeats. The findings have important implications for avian immunogenetics and provide a model for studying gene loss via microhomology-mediated events.

• Sensitive Yeast Screening Accelerates Discovery of mTOR Inhi

  2026-04-23

  This study introduces a drug-sensitized yeast platform that enables highly sensitive and selective identification of mTOR inhibitors, surpassing detection limits of traditional assays. The system robustly distinguishes true TOR pathway inhibitors from compounds that act via unrelated mechanisms, offering researchers a rapid and cost-effective tool for advancing aging and metabolic disorder investigations.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-04-22

  This study introduces a peptide amphiphile that employs dual enzyme responsiveness and zwitterionic self-assembly to enable highly selective cancer cell targeting. The approach leverages sequential enzymatic disassembly and assembly within lysosomes, resulting in selective cytotoxicity toward cancer cells while sparing normal tissues, presenting a promising advance in precision peptide-based cancer therapeutics.

• Mutational Landscape of Myeloma Cell Lines: Insights for Dru

  2026-04-22

  This study provides the first comprehensive exome-wide characterization of human multiple myeloma cell lines (HMCLs), identifying 236 recurrently mutated protein-coding genes and key altered pathways implicated in tumor progression and drug resistance. The findings establish an essential genomic resource for selecting relevant in vitro models and inform mechanistic studies on therapeutic response and resistance.

• GANT61 as a GLI Inhibitor: Translational Leverage in Tumor I

  2026-04-21

  Explore how GANT61, a potent GLI inhibitor, enables precision targeting of GLI1/2 transcription factors to dissect tumor immune evasion and resistance. This article uniquely connects mechanistic insights and practical assay guidance for advanced cancer research.

408 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page